Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 24, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Cap	42	59	71	60	121	159
Market Cap Growth	-8.71%	-16.43%	17.53%	-50.38%	-23.75%	-
Enterprise Value	32.97	47.53	67.7	48.99	106.84	139.22
PE Ratio	-	-5.76	-8.53	-5.00	-17.93	-2.41
PB Ratio	5.29	5.07	18.57	5.68	8.06	7.44
P/TBV Ratio	5.33	4.18	18.49	5.56	8.06	4.34
P/FCF Ratio	-	-9.32	-8.75	-6.22	-22.33	-32.68
P/OCF Ratio	-	-9.32	-8.75	-6.22	-22.33	-32.68
EV/EBITDA Ratio	-	-5.38	-8.30	-4.16	-15.64	-38.53
EV/EBIT Ratio	-	-5.15	-8.15	-4.16	-15.64	-38.53
EV/FCF Ratio	-	-7.49	-8.37	-5.06	-19.65	-28.58
Net Debt / Equity Ratio	-1.14	-1.00	-0.81	-1.06	-0.97	-0.93
Net Debt / EBITDA Ratio	1.03	1.32	0.38	0.95	2.13	5.53
Net Debt / FCF Ratio	1.55	1.83	0.38	1.16	2.68	4.10
Quick Ratio	6.12	23.99	11.87	10.52	28.39	82.71
Current Ratio	6.24	24.53	13.46	10.92	30.40	89.61
Return on Equity (ROE)	-69.69%	-109.69%	-113.80%	-91.42%	-37.42%	-249.85%
Return on Assets (ROA)	-72.07%	-113.74%	-105.55%	-86.49%	-36.69%	-29.28%
Return on Invested Capital (ROIC)	1595.31%	-2464.82%	-22991.10%	18466.12%	-702.56%	-513.63%
Return on Capital Employed (ROCE)	-79.51%	-119.24%	-115.29%	-91.81%	-37.45%	-29.85%
Earnings Yield	-18.99%	-17.36%	-11.72%	-20.00%	-5.58%	-41.50%
FCF Yield	-	-10.73%	-11.43%	-16.07%	-4.48%	-3.06%
Buyback Yield / Dilution	-	-25.35%	0.00%	-11.12%	0.00%	-12.94%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.